Inja Waldhauer
Senior Principal Scientist Roche
Inja Waldhauer is a Senior Principal Scientist at the Roche Innovation Center Zurich, where she has contributed her expertise since 2008. With extensive experience in the development of T-cell engagers, costimulators, and cytokines, she has successfully guided numerous projects from initial discovery concepts through to early clinical studies. Over her tenure, she has authored multiple scientific publications and contributed to numerous patent applications in the field of cancer immunotherapy.
Seminars
Wednesday 9th December 2026
Next-Generation T-Cell Engagers: Leveraging Protease Activation to Overcome Toxicity & Expand the Therapeutic Window
4:30 pm
- The efficacy of T-cell engagers in solid tumors is often limited by systemic toxicities, including on-target/off-tumor effects
- Our next-generation approach utilizes a conditionally-activated platform designed to restrict T-cell engagement to the tumor microenvironment via tumor-associated proteases
- This strategy minimises off-tumor activity and systemic immune activation while maintaining robust anti-tumor efficacy, thereby significantly widening the therapeutic window for treatment
